Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Net Cash Flow (2020 - 2023)

Historic Net Cash Flow for Cullinan Therapeutics (CGEM) over the last 4 years, with Q4 2023 value amounting to $33.6 million.

  • Cullinan Therapeutics' Net Cash Flow rose 13882.67% to $33.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$57.7 million, marking a year-over-year decrease of 15988.71%. This contributed to the annual value of -$15.4 million for FY2024, which is 7326.83% up from last year.
  • As of Q4 2023, Cullinan Therapeutics' Net Cash Flow stood at $33.6 million, which was up 13882.67% from -$77.0 million recorded in Q3 2023.
  • Cullinan Therapeutics' 5-year Net Cash Flow high stood at $277.4 million for Q2 2022, and its period low was -$169.9 million during Q2 2021.
  • Over the past 4 years, Cullinan Therapeutics' median Net Cash Flow value was -$13.8 million (recorded in 2020), while the average stood at $2.2 million.
  • Over the last 5 years, Cullinan Therapeutics' Net Cash Flow had its largest YoY gain of 80147.19% in 2021, and its largest YoY loss of 306918.37% in 2021.
  • Cullinan Therapeutics' Net Cash Flow (Quarter) stood at $126.9 million in 2020, then tumbled by 122.33% to -$28.3 million in 2021, then plummeted by 205.34% to -$86.5 million in 2022, then soared by 138.83% to $33.6 million in 2023.
  • Its last three reported values are $33.6 million in Q4 2023, -$77.0 million for Q3 2023, and $19.7 million during Q2 2023.